ArticleEuropean heart journal2018
Targeting myeloperoxidase in inflammatory atherosclerosis.
Article in European heart journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 25 citations in OpenAlex.
- Population Pharmacokinetics of the Novel Myeloperoxidase Inhibitor Mitiperstat.Pharmacology research & perspectives · 2026Article
- Study on the association between neovascularization of culprit lesions and plaque rupture in patients with acute myocardial infarction.BMC cardiovascular disorders · 2025Article
- Neovascularization in Atherosclerotic Plaques: Clinical Implications, Detection, and Prevention Strategies.Reviews in cardiovascular medicine · 2025Review
- Photodynamic Therapy for Atherosclerosis.International journal of molecular sciences · 2024Review
- Biomimetic nanomedicines for precise atherosclerosis theranostics.Acta pharmaceutica Sinica. B · 2023Review
- Role of neutrophils in different stages of atherosclerosis.Innate immunity · 2023Review
- Inflammatory Factors Driving Atherosclerotic Plaque Progression New Insights.Journal of translational internal medicine · 2022Article
- Atherosclerosis in Fabry Disease-A Contemporary Review.Journal of clinical medicine · 2021Review
- Recent Updates and Advances in Winiwarter-Buerger Disease (Thromboangiitis Obliterans): Biomolecular Mechanisms, Diagnostics and Clinical Consequences.Diagnostics (Basel, Switzerland) · 2021Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.